25 mg
Trade Name
Amvuttra
Solution for injection
Request Type
Registration
Drug Type
New Drug
Approval Date
SFDA Approved Use
Vutrisiran is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.